Lymph node metastasis is a major contributor to poor prognosis in lung cancer, but the metabolic mechanisms that enable tumor cells to spread to lymph nodes have remained poorly understood. A study published in Cancer Biology & Medicine (CBM) now identifies a primary lymph node metastatic cancer cell (PLMC) subgroup characterized by MOCCI-driven oxidative phosphorylation (OXPHOS) reprogramming, shedding light on how metabolic adaptation fuels immune remodeling during cancer dissemination.
MOCCI, short for Modulator of Cytochrome C Oxidase during Inflammation, functions as a component of mitochondrial complex IV under inflammatory conditions. Researchers at Fudan University Shanghai Cancer Center, with collaborators at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, analyzed matched primary tumors, metastatic and uninvolved lymph nodes, and peripheral blood from 10 patients with lung cancer. They profiled 37 samples by single-cell RNA sequencing and 27 tissue samples by spatial transcriptomics, capturing 671,467 cells across the two datasets. The team also used T-cell and B-cell receptor sequencing, functional assays, mouse models, and an independent clinical cohort of 875 lung cancer cases.
The findings show that PLMCs had significant enrichment of the OXPHOS pathway, and MOCCI expression correlated with OXPHOS activity. MOCCI knockdown in PC9 and A549 lung cancer cells reduced migration and invasion by more than 50% compared with controls. MOCCI overexpression increased mitochondrial respiration and reactive oxygen species generation and promoted lymph node metastasis in mice. MOCCI-overexpressing cells secreted more growth differentiation factor 15 (GDF15), and OXPHOS inhibition reduced GDF15 secretion.
Spatial analyses revealed that Tfh cells expressing transforming growth factor beta receptor 2 (TGFBR2) within 40 micrometers of GDF15-positive PLMCs had increased inhibitory signatures and reduced MHC-II signatures compared with those near GDF15-negative PLMCs. This suggests that MOCCI-positive PLMCs, through GDF15–TGFBR2 signaling, promote Tfh cell exhaustion and suppress activation of neighboring B cells, creating an immunosuppressive microenvironment that facilitates metastasis.
In the independent cohort, MOCCI expression was higher in patients with lymph node metastasis and correlated with higher nodal status. In lung adenocarcinoma cohorts, higher MOCCI expression was associated with poorer overall survival. These results position MOCCI as a key driver of PLMC fate and a potential target for intercepting lymph node metastasis.
The authors conclude that these findings link metabolic adaptation to immune remodeling during lung cancer dissemination. The integrated single-cell and spatial multi-omics atlas provides a resource for further exploration of the cellular states and spatial interactions underlying lymph node metastasis. However, the authors note that the multi-omics cohort included only 10 patients and that spatial heterogeneity limited the identification of shared characteristics. They call for validation in larger cohorts and further experimental studies of the mechanisms underlying metastasis establishment and microenvironment remodeling.
The study, published with DOI 10.20892/j.issn.2095-3941.2025.0587, was supported by the National Key R&D Program of China and the National Natural Science Foundation of China, among others. For more information about the journal, visit http://chuanlink-innovations.com.


